Pre-clinical toxicology studies generate complex datasets that require robust interpretation to identify potential safety liabilities early in drug development. QIAGEN Ingenuity Pathway Analysis (IPA) can help uncover mechanistic insights, predict toxicity outcomes and support decision-making in pre-clinical safety assessments. Explore how you can apply IPA to ‘omics data to identify toxicity signatures, understand mode of action (MoA) and prioritize biomarkers.

· Overview of QIAGEN Ingenuity Pathway Analysis

· Find transcriptomic and proteomic data from pre-clinical and clinical studies and gain mechanistic insights using OmicSoft Explorer and Ingenuity Pathway Analysis

· Visualize and interpret complex biological relationships that may be behind toxicity mechanisms using network construction

· Prioritize candidate biomarkers for safety monitoring using biomarker tools and OmicSoft Land Explorer